Page last updated: 2024-12-07

razadyne

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Razadyne (felodipine) is a calcium channel blocker used to treat high blood pressure. It is a dihydropyridine derivative, and its synthesis involves a complex multi-step process. Razadyne works by relaxing blood vessels, which lowers blood pressure. It is important for managing hypertension, as uncontrolled high blood pressure can lead to serious health complications. Razadyne is studied to understand its efficacy, safety, and potential for treating other cardiovascular conditions. It is generally well-tolerated, but potential side effects include dizziness, headache, and swelling in the ankles.'

Razadyne: Name of the FDA approved preparation from J&J. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121587
CHEMBL ID1555
SCHEMBL ID177993
MeSH IDM0380976

Synonyms (112)

Synonym
HY-A0009
galanthamine (hydrobromide)
reminyl
nivalin
galantamine hydrobromide ,
razadyne
gp-37267
jilkon hydrobromide
galantamine hydrobromide [usan]
lycoremine hydrobromide
nivaline (pharmaceutical)
benzofuro(4,3,2-efg)(2)benzazocin-6-ol, 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-, hydrobromide
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol hydrobromide
r-113675
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4as,6r,8as)-
einecs 217-780-5
nivaline
reminyl xl
razadyne er
galanthamine hydrobromide
1953-04-4
anti-alzheimer
PRESTWICK_236
MLS001401401
galanthamine hydrobromide from lycoris sp., >=94% (tlc)
smr000449267
MLS000758283
razadyne (tn)
reminyl (tn)
galantamine hydrobromide (jan/usp)
D02173
SPECTRUM1501202
AC-469
G0293
CHEMBL1555
(-)-galantamine hydrobromide
tamilin
HMS1921P21
HMS1569F18
AKOS007930166
unii-mj4ptd2vvw
mj4ptd2vvw ,
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide (1:1), (4as,6r,8as)-
galantamine hydrobromide [usan:usp]
jilcon hydrobromide
AKOS015960209
CCG-38829
galantamine hydrobromide [who-dd]
galantamine hydrobromide [mi]
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hbr (1:1), (4as,6r,8as)-
galantamine hydrobromide [jan]
galantamine hydrobromide [usp-rs]
galantamine hydrobromide [ep monograph]
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hbr, (4as,6r,8as)-
galantamine hydrobromide [vandf]
galantamine hydrobromide [orange book]
galantamine hydrobromide [hsdb]
galantamine hydrobromide [mart.]
galantamine hydrobromide [usp monograph]
CS-0378
S1339
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
QORVDGQLPPAFRS-XPSHAMGMSA-N
NC00061
SCHEMBL177993
galanthaminehydrobromide
(4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol hydrobromide
4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
FD10095
(4as,6r,8as)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6h-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol hydrobromide
galantamine hydrobromide racemic [usp-rs]
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4a.alpha.,6.beta.,8ar*)-
mfcd00067672
SR-01000597844-1
SR-01000597844-5
sr-01000597844
193146-85-9
unii-5n4sa4kqx9
galantamine hydrobromide, (+/-)-
galantamine hydrobromide (racemic)
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide (1:1), (4ar,6s,8ar)-rel-
(+/-)-galantamine hydrobromide
5n4sa4kqx9 ,
6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4aalpha,6beta,8ar*)-
(+/-)-galanthamine hydrobromide
SR-05000001783-3
sr-05000001783
Q47495772
Z1557400300
galanthamine hydrobromide,(s)
AS-12155
1953-04-4 (hbr); 1953-04-4 (free base).
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, hydrobromide
A903748
A866857
nivalin;razadyne
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azoniatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;bromide
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-ol;hydrobromide
(4as,6r,8as)-3-methoxy-11-methyl-5,6,9,10,11,12-hexahydro-4ah-benzo[2,3]benzofuro[4,3-cd]azepin-6-olhydrobromide
(1s,12s,14r)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol hydrobromide
EN300-123969
galanthamine-d3 hydrobromide
galanthamine-o-methyl-d3 hydrobromide
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-d3-11-methyl-6h-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
1953-04-4 unlabeled
galantamine hydrobromide (mart.)
galantamine hydrobromide (ep monograph)
galantamine hydrobromide (usan:usp)
galantamine hydrobromide (usp-rs)
dtxcid001473878
galantamine hydrobromide (usp monograph)
(4as,6r,8as)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6h-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol monohydrobromide

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Intravenous and oral 6-h blood sampling profiles in old (30 months old) and young (7 months old) rats revealed pharmacokinetic changes similar to those in humans with an approximately 40% increase in C(max) of galantamine and prolonged t(1/2) (1."( Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
Aw, CC; Browne, ER; Chen, CP; Goh, CW; Lee, JH, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency14.81120.000811.382244.6684AID686978; AID686979
IDH1Homo sapiens (human)Potency8.19950.005210.865235.4813AID686970
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency6.30960.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency6.30960.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency6.30960.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency20.72410.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AcetylcholinesteraseElectrophorus electricus (electric eel)IC50 (µMol)0.66750.00000.94539.9400AID1417296; AID1887295; AID383238; AID483165
AcetylcholinesteraseElectrophorus electricus (electric eel)Ki0.47670.00121.25638.9000AID1153971; AID1233122; AID1286151; AID1337877; AID1379120; AID1417298; AID1435998; AID1597595; AID383238
AcetylcholinesteraseTetronarce californica (Pacific electric ray)IC50 (µMol)1.06950.00570.42855.1200AID1241005
CholinesteraseHomo sapiens (human)IC50 (µMol)50.00000.00001.559910.0000AID1436087
AcetylcholinesteraseHomo sapiens (human)IC50 (µMol)3.20000.00000.933210.0000AID1436088; AID592640; AID621448
CholinesteraseEquus caballus (horse)IC50 (µMol)10.95200.00002.22149.4000AID378844; AID383239; AID404058; AID483166; AID621449
CholinesteraseEquus caballus (horse)Ki6.26250.00203.45989.3700AID1153972; AID1286153; AID1337879; AID1436000
Carboxylic ester hydrolase Equus caballus (horse)IC50 (µMol)12.60000.00512.69848.5000AID592641
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (25)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processCholinesteraseHomo sapiens (human)
learningCholinesteraseHomo sapiens (human)
negative regulation of cell population proliferationCholinesteraseHomo sapiens (human)
neuroblast differentiationCholinesteraseHomo sapiens (human)
peptide hormone processingCholinesteraseHomo sapiens (human)
response to alkaloidCholinesteraseHomo sapiens (human)
cocaine metabolic processCholinesteraseHomo sapiens (human)
negative regulation of synaptic transmissionCholinesteraseHomo sapiens (human)
response to glucocorticoidCholinesteraseHomo sapiens (human)
response to folic acidCholinesteraseHomo sapiens (human)
choline metabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic processCholinesteraseHomo sapiens (human)
acetylcholine catabolic process in synaptic cleftAcetylcholinesteraseHomo sapiens (human)
regulation of receptor recyclingAcetylcholinesteraseHomo sapiens (human)
osteoblast developmentAcetylcholinesteraseHomo sapiens (human)
acetylcholine catabolic processAcetylcholinesteraseHomo sapiens (human)
cell adhesionAcetylcholinesteraseHomo sapiens (human)
nervous system developmentAcetylcholinesteraseHomo sapiens (human)
synapse assemblyAcetylcholinesteraseHomo sapiens (human)
receptor internalizationAcetylcholinesteraseHomo sapiens (human)
negative regulation of synaptic transmission, cholinergicAcetylcholinesteraseHomo sapiens (human)
amyloid precursor protein metabolic processAcetylcholinesteraseHomo sapiens (human)
positive regulation of protein secretionAcetylcholinesteraseHomo sapiens (human)
retina development in camera-type eyeAcetylcholinesteraseHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholinesteraseHomo sapiens (human)
positive regulation of cold-induced thermogenesisAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
amyloid-beta bindingCholinesteraseHomo sapiens (human)
catalytic activityCholinesteraseHomo sapiens (human)
acetylcholinesterase activityCholinesteraseHomo sapiens (human)
cholinesterase activityCholinesteraseHomo sapiens (human)
protein bindingCholinesteraseHomo sapiens (human)
hydrolase activity, acting on ester bondsCholinesteraseHomo sapiens (human)
enzyme bindingCholinesteraseHomo sapiens (human)
choline bindingCholinesteraseHomo sapiens (human)
identical protein bindingCholinesteraseHomo sapiens (human)
amyloid-beta bindingAcetylcholinesteraseHomo sapiens (human)
acetylcholinesterase activityAcetylcholinesteraseHomo sapiens (human)
cholinesterase activityAcetylcholinesteraseHomo sapiens (human)
protein bindingAcetylcholinesteraseHomo sapiens (human)
collagen bindingAcetylcholinesteraseHomo sapiens (human)
hydrolase activityAcetylcholinesteraseHomo sapiens (human)
serine hydrolase activityAcetylcholinesteraseHomo sapiens (human)
acetylcholine bindingAcetylcholinesteraseHomo sapiens (human)
protein homodimerization activityAcetylcholinesteraseHomo sapiens (human)
laminin bindingAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
extracellular regionCholinesteraseHomo sapiens (human)
nuclear envelope lumenCholinesteraseHomo sapiens (human)
endoplasmic reticulum lumenCholinesteraseHomo sapiens (human)
blood microparticleCholinesteraseHomo sapiens (human)
plasma membraneCholinesteraseHomo sapiens (human)
extracellular spaceCholinesteraseHomo sapiens (human)
extracellular regionAcetylcholinesteraseHomo sapiens (human)
basement membraneAcetylcholinesteraseHomo sapiens (human)
extracellular spaceAcetylcholinesteraseHomo sapiens (human)
nucleusAcetylcholinesteraseHomo sapiens (human)
Golgi apparatusAcetylcholinesteraseHomo sapiens (human)
plasma membraneAcetylcholinesteraseHomo sapiens (human)
cell surfaceAcetylcholinesteraseHomo sapiens (human)
membraneAcetylcholinesteraseHomo sapiens (human)
neuromuscular junctionAcetylcholinesteraseHomo sapiens (human)
synaptic cleftAcetylcholinesteraseHomo sapiens (human)
synapseAcetylcholinesteraseHomo sapiens (human)
perinuclear region of cytoplasmAcetylcholinesteraseHomo sapiens (human)
side of membraneAcetylcholinesteraseHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1153973Selectivity ratio of Ki for Electrophorus electricus AChE to Ki for equine serum BChE2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Amino derivatives of glycyrrhetinic acid as potential inhibitors of cholinesterases.
AID1220472Dose normalized AUC (0 to t) in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220479Inhibition of cholinesterase activity in 7 months-old Lister Hooded rat brain at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID621449Inhibition of equine BuChE by Ellman's method2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
AID1220470Half life in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1436000Competitive inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured every 1 min for 30 mins by Dixon plot method2017European journal of medicinal chemistry, Jan-27, Volume: 126Amino derivatives of platanic acid act as selective and potent inhibitors of butyrylcholinesterase.
AID1220462Cmax in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1241005Inhibition of Torpedo californica AChE using ATCI substrate incubated for 30 mins by Ellman's method based spectrophotometry2015Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17
Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity.
AID1417295Inhibition of electric eel AChE at 10 M using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1220464Dose normalized AUC (0 to t) in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID592641Inhibition of equine BChE incubated with compounf for 5 mins before addition of substrate S-butyrylthiocholine iodide by Ellman's method2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220458Half life in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1153972Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate after 20 mins measured for 1 min interval for 30 mins by Ellman's method2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Amino derivatives of glycyrrhetinic acid as potential inhibitors of cholinesterases.
AID1220465Dose normalized AUC (0 to infinity) in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220487Clearance in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220471Mean residence time in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220475Tmax in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220459Mean residence time in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220478Oral bioavailability in 30 months-old Lister Hooded rat at 3 mg/kg2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220499Drug uptake in 7 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1379120Competitive inhibition of electric eel AChE assessed as inhibition constant for enzyme inhibitor complex preincubated for 20 mins followed by acetylthiocholine iodide substrate addition and measured for 30 mins at 1 min intervals by Ellman's method2017European journal of medicinal chemistry, Oct-20, Volume: 139Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase.
AID1220467Cmax in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220474Cmax in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1233122Inhibition of Electrophorus electricus acetylcholinesterase using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured for 30 mins by Ellman's method2015Bioorganic & medicinal chemistry letters, Jul-01, Volume: 25, Issue:13
Allobetulin derived seco-oleananedicarboxylates act as inhibitors of acetylcholinesterase.
AID483168Selectivity ratio of IC50 for electric eel AChE to IC50 for horse serum BChE2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase.
AID1597603Inhibition of electric eel AChE at 10 uM using acetylcholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured every minute for 30 mins by Ellman's method relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177Caffeic acid phenethyl ester (CAPE)-derivatives act as selective inhibitors of acetylcholinesterase.
AID1220513Blood clearance in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID621451Inhibition of human AChE-induced amyloid beta (1-40) aggregation at 100 uM after 24 hrs by thioflavin T-based fluorometric assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
AID592642Selectivity index, ratio of IC50 for human AChE to IC50 for equine BChE2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220503Drug uptake in 30 months-old Lister Hooded rat assessed as corrected brain concentration at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID378844Inhibition of horse serum BuChE by Ellman's method2006Journal of natural products, Oct, Volume: 69, Issue:10
Microbial transformation and butyrylcholinesterase inhibitory activity of (-)-caryophyllene oxide and its derivatives.
AID1379118Inhibition of electric eel AChE at 50 uM preincubated for 20 mins followed by acetylthiocholine iodide substrate addition and measured for 30 mins at 1 min intervals by Ellman's method relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase.
AID1220491Drug excretion in human feces at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID621448Inhibition of human AChE by Ellman's assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
AID383238Inhibition of Electrophorus electricus AChE by Ellman's method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors.
AID1286153Inhibition of equine serum BChE using butyrylthiocholine iodide as substrate preincubated for 20mins before the addition of substrate by Ellman's method2015European journal of medicinal chemistry, Oct-20, Volume: 103Converting maslinic acid into an effective inhibitor of acylcholinesterases.
AID1220490Drug excretion in human urine assessed as unchanged drug level at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220468Blood clearance in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID592640Inhibition of human AChE incubated with compounf for 5 mins before addition of substrate acetylthiocholine iodide by Ellman's method2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220477Dose normalized AUC (0 to infinity) in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1220501Ratio of brain to blood in 7 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID621450Selectivity index, ratio of IC50 for human AChE to IC50 for equine BuChE2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
AID1436002Selectivity ratio of Ki for equine serum BChE to Ki for electric eel AChE2017European journal of medicinal chemistry, Jan-27, Volume: 126Amino derivatives of platanic acid act as selective and potent inhibitors of butyrylcholinesterase.
AID404058Inhibition of horse serum BChE by Ellman's reaction2005Journal of natural products, Dec, Volume: 68, Issue:12
Nostocarboline: isolation and synthesis of a new cholinesterase inhibitor from Nostoc 78-12A.
AID1153971Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate after 20 mins measured for 1 min interval for 30 mins by Ellman's method2014Bioorganic & medicinal chemistry, Jul-01, Volume: 22, Issue:13
Amino derivatives of glycyrrhetinic acid as potential inhibitors of cholinesterases.
AID1220486Volume of distribution in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID592645Cytotoxicity against human SH-SY5Y cells assessed as cell viability after 24 hrs by MTT-based colorimetric assay2011Bioorganic & medicinal chemistry, Apr-01, Volume: 19, Issue:7
Design, synthesis and structure-activity relationship (SAR) studies of 2,4-disubstituted pyrimidine derivatives: dual activity as cholinesterase and Aβ-aggregation inhibitors.
AID1220502Drug uptake in 30 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220484Tmax in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220497Inhibition of acetylcholinesterase activity in 30 months-old Lister Hooded rat brain assessed as percent enhancement of inhibition at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220473Dose normalized AUC (0 to infinity) in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220504Ratio of brain to blood in 30 months-old Lister Hooded rat blood at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220483Plasma protein binding in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID483165Inhibition of electric eel AChE after 15 mins by Ellman's method2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase.
AID1220469Volume of distribution in 30 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220476Dose normalized AUC (0 to t) in 30 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1417297Inhibition of equine serum BuChE at 10 M using butyrylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1337879Competitive inhibition of equine serum butyrylcholinesterase in presence of varying butyrylthiocholine iodide substrate level preincubated for 20 mins followed by substrate addition measured every 1 min for 30 mins2017European journal of medicinal chemistry, Jan-05, Volume: 125Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases.
AID1220460Dose normalized AUC (0 to t) in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1379119Inhibition of equine serum BChE at 50 uM preincubated for 20 mins followed by butyrylthiocholine iodide substrate addition and measured for 30 mins at 1 min intervals by Ellman's method relative to control2017European journal of medicinal chemistry, Oct-20, Volume: 139Piperlongumine B and analogs are promising and selective inhibitors for acetylcholinesterase.
AID1435998Competitive inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition measured every 1 min for 30 mins by Dixon plot method2017European journal of medicinal chemistry, Jan-27, Volume: 126Amino derivatives of platanic acid act as selective and potent inhibitors of butyrylcholinesterase.
AID1220489Drug excretion in human urine at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1337877Competitive inhibition of Electrophorus electricus acetylcholinesterase in presence of varying acetylthiocholine iodide substrate level preincubated for 20 mins followed by substrate addition measured every 1 min for 30 mins2017European journal of medicinal chemistry, Jan-05, Volume: 125Repurposing N,N'-bis-(arylamidino)-1,4-piperazinedicarboxamidines: An unexpected class of potent inhibitors of cholinesterases.
AID1286151Inhibition of Electrophorus electricus AChE using acetylthiocholine iodide as substrate preincubated for 20mins before the addition of substrate by Ellman's method2015European journal of medicinal chemistry, Oct-20, Volume: 103Converting maslinic acid into an effective inhibitor of acylcholinesterases.
AID1061162Inhibition of rat brain AChE using acetylthiocholine iodide/DTNB as substrate at 10 mM preincubated for 30 mins by Ellman's spectrophotometric analysis2014Bioorganic & medicinal chemistry, Jan-01, Volume: 22, Issue:1
Synthesis and evaluation of (-)- and (+)-[¹¹C]galanthamine as PET tracers for cerebral acetylcholinesterase imaging.
AID383240Selectivity ratio of IC50 for Electrophorus electricus AChE to IC50 for horse serum BuChE2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors.
AID1597595Mixed inhibition of electric eel AChE using acetylcholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured every minute for 30 mins by Lineweaver-Burk plot analysis2019European journal of medicinal chemistry, Sep-01, Volume: 177Caffeic acid phenethyl ester (CAPE)-derivatives act as selective inhibitors of acetylcholinesterase.
AID1436087Inhibition of human BuChE using S-butyrylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 60 to 300 secs by Ellman's method2017European journal of medicinal chemistry, Jan-27, Volume: 1262,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
AID1220461Dose normalized AUC (0 to infinity) in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID621452Inhibition of amyloid beta (1 to 40) self-aggregation at 100 uM after 24 hrs by thioflavin T-based fluorometric assay2011Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19
Development of 2-substituted-N-(naphth-1-ylmethyl) and N-benzhydrylpyrimidin-4-amines as dual cholinesterase and Aβ-aggregation inhibitors: Synthesis and biological evaluation.
AID1220512Cmax in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220463Tmax in 7 months-old Lister Hooded rat at 3 mg/kg, po2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1887295Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 30 mins followed by substrate addition and measured after 5 mins by DTNB-reagent based Ellman's method2022Journal of natural products, 09-23, Volume: 85, Issue:9
Zamamiphidins B and C, Manzamine-Related Alkaloids from an
AID483166Inhibition of horse serum BChE after 15 mins by Ellman's method2010Bioorganic & medicinal chemistry letters, Jun-01, Volume: 20, Issue:11
Synthesis of 4-[(diethylamino)methyl]-phenol derivatives as novel cholinesterase inhibitors with selectivity towards butyrylcholinesterase.
AID383239Inhibition of horse serum BuChE by Ellman's method2008European journal of medicinal chemistry, Jan, Volume: 43, Issue:1
Synthesis and biological evaluation of helicid analogues as novel acetylcholinesterase inhibitors.
AID1220466Oral bioavailability in 7 months-old Lister Hooded rat at 3 mg/kg2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220500Drug uptake in 7 months-old Lister Hooded rat assessed as corrected brain concentration at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1597602Inhibition of equine serum BChE at 10 uM using butyrylcholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured every minute for 30 mins by Ellman's method relative to control2019European journal of medicinal chemistry, Sep-01, Volume: 177Caffeic acid phenethyl ester (CAPE)-derivatives act as selective inhibitors of acetylcholinesterase.
AID1220488Oral bioavailability in human at 2 mg single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220457Volume of distribution in 7 months-old Lister Hooded rat at 1 mg/kg, iv infusion for 1 hr2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1417298Competitive inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Lineweaver-Burk plot analysis2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1436088Inhibition of human AChE using acetylthiocholine iodide as substrate preincubated for 5 mins followed by substrate addition measured for 60 to 300 secs by Ellman's method2017European journal of medicinal chemistry, Jan-27, Volume: 1262,4-Disubstituted quinazolines as amyloid-β aggregation inhibitors with dual cholinesterase inhibition and antioxidant properties: Development and structure-activity relationship (SAR) studies.
AID1220480Inhibition of cholinesterase activity in 7 months-old Lister Hooded rat plasma at 3 mg/kg, po after 1 hr treatment2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1220485Half life in human at 2 mg, po single dose2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats.
AID1417296Inhibition of electric eel AChE using acetylthiocholine iodide as substrate preincubated for 20 mins followed by substrate addition and measured at 1 min intervals for 30 mins by Ellman's method2018Bioorganic & medicinal chemistry letters, 11-01, Volume: 28, Issue:20
Unexpected AChE inhibitory activity of (2E)α,β-unsaturated fatty acids.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (14.29)29.6817
2010's22 (78.57)24.3611
2020's2 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.12 (24.57)
Research Supply Index3.37 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index87.87 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (56.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other27 (96.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]